Loading…
Loading…
ELVAF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ELVAF and 80,000+ other tickers.
See exactly how ELVAF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ELVAF and 80,000+ other tickers.
EvoNext Holdings SA focuses on the discovery, refinement, and market introduction of innovative components for nutritional, healthcare, and general wellness applications. This enterprise was established in 2004 by Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith, and maintains its primary base of operations in Reinach, Switzerland.
Evolva Holding SA (OTCPK:ELVAF) Q2 2023 Earnings Call Transcript August 24, 2023 3:00 AM ET Company Participants Christian Wichert - CEO Carsten Daweritz - CFO Conference Call Participants Daniel Burki - Zurcher Kantonalbank Laura Pfeifer - Octavian Operator Good morning, ladies and gentlemen, and welcome to the Evolva presentation regarding the half year 2023 results. At this time, all participants have been placed on a listen-only mode.
Evolva Holding SA (OTCPK:ELVAF) Q4 2022 Earnings Conference Call March 9, 2023 4:00 AM ET Company Participants Christian Wichert - Chief Executive Officer Doris Rudischhauser - Head, Corporate Communications and Investor Relations Carsten Daweritz - Chief Financial Officer Philipp Frech - General Counsel Conference Call Participants Henrietta Rumberger - awp Laura Pfeifer - Octavian Jonathan Herbert - Cologny Advisors Operator Ladies and gentlemen, a warm welcome to the Evolva Full Year 2022 Results Presentation. [Operator Instructions] Let me now turn the floor over to Christian Wichert, the CEO of Evolva.
REINACH, Switzerland--(BUSINESS WIRE)--Evolva Holding SA (“Evolva”, SIX:EVE) today announced that Emergent BioSolutions Inc. (“Emergent”, NYSE:EBS) has acquired Evolva’s anti-bacterial programme, the EV-035 series. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. For Evolva, this transaction is worth up to USD 70.5 million plus royalties. GC-072 has shown efficacy in both in vitro and in vivo studies against a wide range of bacterial pathogens, most notably Burkholderia pseudomallei. This bacterium causes the disease melioidosis and is regarded as a potential bio-threat agent. The preclinical development of GC-072 is funded by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense. Evolva and Emergent are working closely with DTRA on the transfer of the funding contract to Emergent, and expect this process to be completed within the next few weeks. Evolva will receive from Emergent an upfront payment of USD 1.5 million, an additional USD 4 million after the US government approves transfer of the GC-072 contract to Emergent, development milestone payments up to USD 65 million, and tiered royalties up to a maximum of 10% on product net sales generated from the EV-035 programme. This transaction completes Evolva’s strategic shift of focus towards ingredients for health, wellness and nutrition. Neil Goldsmith, CEO of Evolva, said “We are very pleased to have found a good home for GC-072. Emergent has extensive experience partnering with the U.S. government through its development, manufacture, and delivery of medical countermeasures, and is perfectly placed to make the EV-035 series a success. This is financially an attractive deal for Evolva, both in the short term and the longer term.” “Emergent’s acquisition of the EV-035 series of broad spectrum antibiotics further aligns the company with the U.S. government’s strategic objective of combating antibiotic-resistant bacteria, which the Administration considers a national security priority that requires continued development funding,” said Adam Havey, Executive Vice President and President, Biodefense Division of Emergent BioSolutions. - ends - About EvolvaEvolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video. About GC-072GC-072 is the lead compound of Evolva’s EV-035 series. It is a novel bacterial type II topoisomerase inhibitor, belonging to the chemical class of 4-oxoquinolizine, showing broad-spectrum activity against pathogens such as Staphylococcus, Streptococcus, Enterococcus, Escherichia, Pseudomonas, Acinetobacter and Haemophilus, as well as several potential bio-threat agents. Most importantly, GC-072 shows activity not only on drug-sensitive strains, but also on those resistant to marketed antibiotics (including quinolones). It has a favourable safety profile and has demonstrated efficacy when dosed intravenously or orally in animals. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.